EVALUATION OF CYTOKINE IL-6 PROFILE IN PATIENTS HOSPITALIZED WITH COVID-19 IN THE 15TH REGIONAL HEALTH OF PARANA
Abstract
COVID-19 is a viral infection caused by SARS-CoV-2 coronavirus, discovered in Wuhan,
China, in 2019. It is a potentially serious disease with high transmissibility, characterized by
worsening due to the exacerbated immune response, coordinated from pro-inflammatory
cytokines signaling, leading to tissue damage. Objective: to evaluate the immunological
profile of patients affected by COVID-19 through protein measurement that modulates
immune response and has a great influence on cytokine storms. Materials and methods: the
serum concentration analysis of the cytokine IL-6 was performed in patients with the disease.
This procedure was developed through the duplicate capture ELISA technique, following
manufacturer's standards, with the serum used from University Hospital of Maringa (HUM)
patients who were hospitalized in the ward (G2), and who were in the intensive care unit but
died (G3), as well as negative samples for COVID-19 (G1-control) from blood donors stored
in the Maringa Regional Blood Center. Data were analyzed using GraphPad Prism software,
version 7.0. Results: an increase in IL-6 was observed in more severe patients (G3).
Conclusion: the cytokine IL-6 has been shown to be important prognostic markers of
worsening of COVID-19.
Downloads
Metrics
References
at: <https://covid.saude.gov.br/> Accessed: Oct 24, 2022.
2. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC et al. An update on
COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment
strategies. Expert Rev Anti Infect Ther. 2021 Jul;19(7):877-888. doi:
10.1080/14787210.2021.1863146. Available at:
<https://doi.org/10.1080/14787210.2021.1863146> Accessed: Feb 15, 2023.
3. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential
vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy
Immunol. 2020 Mar;38(1):1-9. doi: 10.12932/AP-200220-0772. Available at:
<https://doi.org/10.12932/ap-200220-0772> Accessed: 15 Feb 2023.
4. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and
coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-
2600(20)30216-2. Available at: <http://dx.doi.org/10.1016/s2213- 2600(20)30216-
2> Accessed: Nov 5, 2022.
5. Silva CC, Carvalho CMO, Lima DC et al. Covid-19: Aspects of origin, pathophysiology,
immunology and treatment: a narrative review. Electronic Journal Health Collection, v.
13, p 1-8, 2021.
6. Tang L, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. Front
Immunol. 2020 Nov 30;11:570993. doi: 10.3389/fimmu.2020.570993. Available at:
<https://doi.org/10.3389/fimmu.2020.570993> Accessed on: Feb 14, 2023.
DECLARAÇÃO DE ORIGINALIDADE E DIREITOS AUTORAIS
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
Os direitos autorais pertencem exclusivamente aos autores. Os direitos de licenciamento utilizados pelo periódico é a licença Creative Commons Attribution 4.0 (CC BY ): são permitidos o acompartilhamento (cópia e distribuição do material em qualqer meio ou formato) e adaptação (remix, transformação e criação de material a partir do conteúdo assim licenciado para quaisquer fins, inclusive comerciais.
Recomenda-se a leitura desse link para maiores informações sobre o tema: fornecimento de créditos e referências de forma correta, entre outros detalhes cruciais para uso adequado do material licenciado.
